Navigation Links
Sanovas Expands Headquarters and Opens Manufacturing Site
Date:1/24/2012

SAUSALITO, Calif., Jan. 24, 2012 /PRNewswire/ -- Sanovas, a leading developer of innovative micro-surgical devices for diagnosing and treating cancer and chronic diseases, announced today that it has expanded its corporate headquarters and opened a manufacturing site in Sausalito, Calif. The facility will initially manufacture critical components of Sanovas' technology ahead of filing for U.S. Food and Drug Administration approval, and would ultimately serve to produce Sanovas' commercial products.

"Sanovas' headquarters is a natural choice for our manufacturing site, as it allows us to maintain the highest level of quality control over the most proprietary components of our technology platform," CEO Larry Gerrans said. "These facilities will provide us with the ability to attract the very best talent from within the life sciences community right here in the Bay Area."

Sanovas' micro-surgical technology platform is designed to give surgeons the ability to access and understand previously inaccessible areas of the body, enabling them to diagnose, treat and deliver drug and immune therapies to small diameter anatomy in entirely new ways. Developed by the pioneers in the field of minimally invasive devices, this intelligent micro-surgical technology platform utilizes the world's smallest surgical camera to visualize and treat difficult-to-reach areas of the body. The camera is connected to the end of a steerable catheter that is further used to deliver additional tools for collecting tissue samples, analyzing and removing tumors and delivering drug and immune therapies to targeted locations within the deepest reaches of the body.

Sanovas plans to file a 510(K) submission with the FDA within the first half of 2012 for approval of its technology, and if approved, would begin full-scale manufacturing by the end of the year. Initially, Sanovas intends to market its micro-surgical tools for the treatment of lung cancer and pulmonary disease. Lung cancer is the leading cause of cancer death among men and women worldwide, and nearly 400,000 people in the United States die from lung disease each year, according to the American Lung Association.

"With nearly one in seven Americans currently suffering from a chronic pulmonary disease and another 96 million at risk, there is an urgent humanitarian need for these next-generation solutions," Gerrans said.

About Sanovas

Sanovas, Inc., based in Sausalito, Calif., is a leading developer of innovative micro-surgical devices for diagnosing and treating cancer and chronic diseases. Sanovas' micro-surgical technology platform is designed to give surgeons the ability to access and visualize previously inaccessible areas of the body; enabling them to diagnose, treat and deliver drug and immune therapies to small diameter anatomy in entirely new ways. The company plans to commercialize its technology platform, which will initially address the unmet needs in lung cancer and pulmonary disease, in 2012. Privately held Sanovas was founded by the pioneers in minimally invasive surgery. The company has more than 25 multi-national patents pending.

Media Contacts:                                        
Racepoint Group
For Sanovas
Marla Kertzman, 415-694-6701


'/>"/>
SOURCE Sanovas
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Sanovas CEO Larry Gerrans Featured Speaker at AdvaMed 2011
2. Biodel Inc. Expands Ongoing Phase III VIAject(TM) Clinical Trials Into Europe
3. BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
4. Cellectar Expands Clinical Management Team
5. VIA Pharmaceuticals Expands Clinical Trial Program for VIA-2291 in Acute Coronary Syndrome
6. PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
7. Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkins Lymphoma
8. PAREXEL Expands Global Clinical Pharmacology Capabilities
9. BiPar Sciences Expands Clinical Program for BSI-201, a Novel DNA Repair Inhibitor, in Brain Cancer
10. Senesco Expands on Recently Announced Preclinical Pancreatic Islet Data
11. Alseres Pharmaceuticals Expands Sites for the First Stage of the ALTROPANE(R) Phase III Clinical Trial Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... FRISCO, Texas , Oct. 11, 2017 /PRNewswire/ ... healthcare services, has amplified its effort during National ... patients about hereditary cancer risks. ... Journal of Clinical Oncology calculated that more than ... to have inherited mutations in BRCA1 or BRCA2 and ...
(Date:10/7/2017)...   Provista, a proven leader in the ... purchasing power, today announced a new resource area on ... is the online home for case studies, articles ... news releases, slideshows and events. ... resources at their fingertips, viewers can also watch short ...
(Date:10/4/2017)... LAWRENCE, Mass. , Oct. 4, 2017 /PRNewswire/ ... developer of single-use, self-contained, illuminating medical devices, today ... National Health Surveillance Agency (or Agência Nacional ... ®. The first single-use, cordless surgical retractor with ... ONETRAC provides optimal access, illumination and exposure of ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), one of ... innovative new design of the shoulder pad. The shoulder pad provides optimal support ... your pain while using cold therapy. By utilizing ice and water that is circulated ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... that we intend to develop to enable prevention of a major side effect ... hearing loss, especially in pediatric patients. For cisplatin, hearing loss is FDA listed ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at Children’s National ... 49th Congress of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. ... for Cancer and Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., ...
(Date:10/12/2017)... ... October 12, 2017 , ... Health ... interactive health literacy software tool, and the Cancer Patient Education Network (CPEN), an ... education, today announce a new strategic alliance. , As CPEN’s strategic partner, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Farm Forward ... Berkeley, and other leading institutions in announcing the launch of the Leadership ... the way animals are raised for food. , Founding members of the Leadership ...
Breaking Medicine News(10 mins):